Literature DB >> 28625979

Intestine-Specific Homeobox Gene ISX Integrates IL6 Signaling, Tryptophan Catabolism, and Immune Suppression.

Li-Ting Wang1, Shyh-Shin Chiou2,3, Chee-Yin Chai4, Edward Hsi5, Kazunari K Yokoyama1,6,7,8, Shen-Nien Wang9,10,11, Shau-Ku Huang12,13,14,15, Shih-Hsien Hsu9,6,16.   

Abstract

The intestine-specific homeobox transcription factor intestine-specific homeobox (ISX) is an IL6-inducible proto-oncogene implicated in the development of hepatocellular carcinoma, but its mechanistic contributions to this process are undefined. In this study, we provide evidence that ISX mediates a positive feedback loop integrating inflammation, tryptophan catabolism, and immune suppression. We found that ISX-mediated IL6-induced expression of the tryptophan catabolic enzymes Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase in hepatocellular carcinoma cells, resulting in an ISX-dependent increase in the tryptophan catabolite kynurenine and its receptor aryl hydrocarbon receptor (AHR). Activation of this kynurenine/AHR signaling axis acted through a positive feedback mechanism to increase ISX expression and enhance cellular proliferation and tumorigenic potential. RNAi-mediated attenuation of ISX or AHR reversed these effects. In an IDO1-dependent manner, ectopic expression of ISX induced expression of genes encoding the critical immune modulators CD86 (B7-2) and programmed death ligand-1 (PD-L1), through which ISX conferred a significant suppressive effect on the CD8+ T-cell response. In hepatocellular carcinoma specimens, expression of IDO1, kynurenine, AHR, and PD-L1 correlated negatively with survival. Overall, our results identified a feed-forward mechanism of immune suppression in hepatocellular carcinoma organized by ISX, which involves kynurenine-AHR signaling and PD-L1, offering insights into immune escape by hepatocellular carcinoma, which may improve its therapeutic management. Cancer Res; 77(15); 4065-77. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28625979     DOI: 10.1158/0008-5472.CAN-17-0090

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.

Authors:  Li-Chuan Chan; Chia-Wei Li; Weiya Xia; Jung-Mao Hsu; Heng-Huan Lee; Jong-Ho Cha; Hung-Ling Wang; Wen-Hao Yang; Er-Yen Yen; Wei-Chao Chang; Zhengyu Zha; Seung-Oe Lim; Yun-Ju Lai; Chunxiao Liu; Jielin Liu; Qiongzhu Dong; Yi Yang; Linlin Sun; Yongkun Wei; Lei Nie; Jennifer L Hsu; Hui Li; Qinghai Ye; Manal M Hassan; Hesham M Amin; Ahmed O Kaseb; Xin Lin; Shao-Chun Wang; Mien-Chie Hung
Journal:  J Clin Invest       Date:  2019-07-15       Impact factor: 14.808

2.  Aryl hydrocarbon receptor-kynurenine axis promotes oncogenic activity in BCP-ALL.

Authors:  Li-Ting Wang; Kwei-Yan Liu; Shen-Nien Wang; Ming-Hong Lin; Yu-Mei Liao; Pei-Chin Lin; Shau-Ku Huang; Shih-Hsien Hsu; Shyh-Shin Chiou
Journal:  Cell Biol Toxicol       Date:  2022-06-10       Impact factor: 6.691

Review 3.  Metabolic regulation of the cancer-immunity cycle.

Authors:  Luis F Somarribas Patterson; Santosha A Vardhana
Journal:  Trends Immunol       Date:  2021-10-02       Impact factor: 16.687

Review 4.  Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma.

Authors:  Kwei-Yan Liu; Li-Ting Wang; Shih-Hsien Hsu
Journal:  Cancers (Basel)       Date:  2018-01-03       Impact factor: 6.639

Review 5.  Targeting the IDO1 pathway in cancer: from bench to bedside.

Authors:  Ming Liu; Xu Wang; Lei Wang; Xiaodong Ma; Zhaojian Gong; Shanshan Zhang; Yong Li
Journal:  J Hematol Oncol       Date:  2018-08-02       Impact factor: 17.388

Review 6.  Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.

Authors:  Kai Tang; Ya-Hong Wu; Yihui Song; Bin Yu
Journal:  J Hematol Oncol       Date:  2021-04-21       Impact factor: 17.388

7.  Impact of AHR Ligand TCDD on Human Embryonic Stem Cells and Early Differentiation.

Authors:  Indrek Teino; Antti Matvere; Martin Pook; Inge Varik; Laura Pajusaar; Keyt Uudeküll; Helen Vaher; Annika Trei; Arnold Kristjuhan; Tõnis Org; Toivo Maimets
Journal:  Int J Mol Sci       Date:  2020-11-28       Impact factor: 5.923

Review 8.  Homeobox Genes and Hepatocellular Carcinoma.

Authors:  Kwei-Yan Liu; Li-Ting Wang; Shih-Hsien Hsu; Shen-Nien Wang
Journal:  Cancers (Basel)       Date:  2019-05-03       Impact factor: 6.639

9.  PCAF-mediated acetylation of ISX recruits BRD4 to promote epithelial-mesenchymal transition.

Authors:  Li-Ting Wang; Kwei-Yan Liu; Wen-Yih Jeng; Cheng-Ming Chiang; Chee-Yin Chai; Shyh-Shin Chiou; Ming-Shyang Huang; Kazunari K Yokoyama; Shen-Nien Wang; Shau-Ku Huang; Shih-Hsien Hsu
Journal:  EMBO Rep       Date:  2020-01-07       Impact factor: 8.807

10.  The trans-omics landscape of COVID-19.

Authors:  Peng Wu; Dongsheng Chen; Wencheng Ding; Ping Wu; Hongyan Hou; Yong Bai; Yuwen Zhou; Kezhen Li; Shunian Xiang; Panhong Liu; Jia Ju; Ensong Guo; Jia Liu; Bin Yang; Junpeng Fan; Liang He; Ziyong Sun; Ling Feng; Jian Wang; Tangchun Wu; Hao Wang; Jin Cheng; Hui Xing; Yifan Meng; Yongsheng Li; Yuanliang Zhang; Hongbo Luo; Gang Xie; Xianmei Lan; Ye Tao; Jiafeng Li; Hao Yuan; Kang Huang; Wan Sun; Xiaobo Qian; Zhichao Li; Mingxi Huang; Peiwen Ding; Haoyu Wang; Jiaying Qiu; Feiyue Wang; Shiyou Wang; Jiacheng Zhu; Xiangning Ding; Chaochao Chai; Langchao Liang; Xiaoling Wang; Lihua Luo; Yuzhe Sun; Ying Yang; Zhenkun Zhuang; Tao Li; Lei Tian; Shaoqiao Zhang; Linnan Zhu; Ashley Chang; Lei Chen; Yiquan Wu; Xiaoyan Ma; Fang Chen; Yan Ren; Xun Xu; Siqi Liu; Jian Wang; Huanming Yang; Lin Wang; Chaoyang Sun; Ding Ma; Xin Jin; Gang Chen
Journal:  Nat Commun       Date:  2021-07-27       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.